Replies to post #4116 on Biotech Values

[DewDiligence]

>> I don't consider the Retaane trial to be a failure in the clinical sense. We have no idea whether or not the patients who respond to Retaane versus Visudyne are overlapping populations, or entirely exclusive populations <<

True, but the Retaane results are not impressive in an absolute sense. After one year, 55% of the Retaane patients had lost 3 or more lines of vision, and few (if any) patients experienced improved vision.

Retaane’s best chance for commercial success may in retarding the progression from dry AMD to wet AMD. Studies testing this are underway and results will be out in about six years.